Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. PureTech Health plc
  6. News
  7. Summary
    PRTC   GB00BY2Z0H74

PURETECH HEALTH PLC

(PRTC)
  Report
Delayed London Stock Exchange  -  11:35:17 2023-01-27 am EST
252.50 GBX   -2.88%
01/10Transcript : PureTech Health plc Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 02:15 PM
CI
01/06PureTech Health Says ADHD Treatment Study Achieves Primary Efficacy Outcome
MT
01/06PureTech says ADHD treatment shows improved attentional functioning
AN
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference

11/01/2022 | 06:04am EST

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced that Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Finance and Operating Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, November 8, 2022, at 12:50pm PST / 3:50pm EST. A webcast of the presentation will be available at https://investors.puretechhealth.com.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221101005203/en/

PureTech’s Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Finance and Operating Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, November 8, 2022, at 12:50pm PST/3:50pm EST (Graphic: Business Wire)

PureTech’s Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Finance and Operating Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, November 8, 2022, at 12:50pm PST/3:50pm EST (Graphic: Business Wire)

About PureTech Health
PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization and a third that will soon be filed for FDA approval, as of the date of PureTech's most recently filed Half-Year Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the Credit Suisse Healthcare Conference and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.


ę Business Wire 2022
All news about PURETECH HEALTH PLC
01/10Transcript : PureTech Health plc Presents at 41st Annual J.P. Morgan Healthca..
CI
01/06PureTech Health Says ADHD Treatment Study Achieves Primary Efficacy Outcome
MT
01/06PureTech says ADHD treatment shows improved attentional functioning
AN
2022TRADING UPDATES: Fiinu teams with TransUnion; GRC wins pact
AN
2022PureTech Provides End of Year Report on Key Progress
BU
2022PureTech Health plc Announces Executive Changes
CI
2022PureTech's LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerabil..
BU
2022PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Tr..
CI
2022PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
BU
2022PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Hea..
AQ
More news
Analyst Recommendations on PURETECH HEALTH PLC
More recommendations
Financials (USD)
Sales 2022 11,3 M - -
Net income 2022 -88,6 M - -
Net cash 2022 398 M - -
P/E ratio 2022 -7,82x
Yield 2022 -
Capitalization 872 M 872 M -
EV / Sales 2022 41,9x
EV / Sales 2023 48,8x
Nbr of Employees 95
Free-Float 84,4%
Chart PURETECH HEALTH PLC
Duration : Period :
PureTech Health plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PURETECH HEALTH PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,13 $
Average target price 7,31 $
Spread / Average Target 134%
EPS Revisions
Managers and Directors
Daphne Zohar Chief Executive Officer & Executive Director
Bharatt M. Chowrira President, COO, CFO, Secretary & Director
Christopher A. Viehbacher Chairman
Joseph B. Bolen Chief Scientific Officer
Julie Krop Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PURETECH HEALTH PLC-5.25%896
MODERNA, INC.7.58%74 239
LONZA GROUP AG17.19%42 748
IQVIA HOLDINGS INC.11.53%42 445
ALNYLAM PHARMACEUTICALS, INC.-2.55%28 492
SEAGEN INC.9.46%25 936